Final FDA Guidance Gives Sponsors More Flexibility In Using Latest Industry Standards For Biologics Submissions
FDA’s biologics center has issued final guidance to sponsors on acceptable practices for using industry standards in developing regulatory submissions for new biologics and drugs.
You may also be interested in...
A US FDA official is exhorting the biopharmaceutical industry to adopt standards to help in developing new cell and gene therapy products, yet this may pose difficulties as there is a lack of standards in this space, particularly in areas such as cell viability, chain of identity and viral vector gene quantification.
Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.
Drug makers win one-month reprieve for their nitrosamine risk assessments for new drug products and approved products.